Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
82 hedge funds and large institutions have $284M invested in Avadel Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 24 increasing their positions, 24 reducing their positions, and 5 closing their positions.
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
5% more funds holding
Funds holding: 78 → 82 (+4)
0.79% more ownership
Funds ownership: 67.03% → 67.82% (+0.79%)
0% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 24
7% less capital invested
Capital invested by funds: $306M → $284M (-$21.3M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $284K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$5.14M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.27M |
| 3 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$1.91M |
| 4 |
Boston Partners
Boston,
Massachusetts
|
+$1.7M |
| 5 |
Renaissance Technologies
New York
|
+$1.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$5.4M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$4.09M |
| 3 |
JGC
J. Goldman & Co
New York
|
-$2.62M |
| 4 |
William Blair & Company
Chicago,
Illinois
|
-$1.99M |
| 5 |
FPC
Falcon Point Capital
San Francisco,
California
|
-$1.85M |
AVDL Hedge Fund Activity: Q3 2017 in Review
82 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q3 2017, worth a combined $284M — down 7% from $306M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new AVDL positions and 5 closed out — a net gain of 6 holders — while 24 added to existing stakes and 24 trimmed.
The largest buyer was Armistice Capital, adding an estimated $5.14M. The largest seller was Broadfin Capital, cutting an estimated $5.4M.
- 82 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q3 2017, up from 78 in Q2 2017.
- Funds reported $284M of Avadel Pharmaceuticals stock for Q3 2017, down 7% quarter-over-quarter.
- 11 funds opened new Avadel Pharmaceuticals positions in Q3 2017 and 5 closed out, a net change of +6 holders.
- The largest Avadel Pharmaceuticals buyer in Q3 2017 was Armistice Capital, an estimated $5.14M added.
- The largest Avadel Pharmaceuticals seller in Q3 2017 was Broadfin Capital, an estimated $5.4M sold.
Based on aggregated 13F filings for Q3 2017.